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OBJECTIVE: Anticoagulation is a challenge for the prophylaxis of thromboembolic events in elderly patients with
chronic atrial fibrillation. Stable anticoagulation is defined as the time within .70% of the therapeutic range.
However, the dosage required to achieve stable anticoagulation remains unknown. The aim of this study was to
analyze the warfarin dose necessary for the maintenance of stable oral anticoagulation therapy in elderly patients.
METHODS: We analyzed 112 consecutive outpatients with atrial fibrillation who were $65 years of age, had
received anticoagulation therapy with warfarin for more than 1 year and had a stable international normalized
ratio between 2.0 and 3.0 for$6 months. The international normalized ratio was measured in the central laboratory
using the traditional method.
RESULTS: The patients were stratified according to the following age groups: ,75 or $75 years and ,80 or $80
years. The mean daily doses of warfarin were similar for patients,75 or$75 years (3.34¡1.71 versus 3.26¡1.27 mg/
day, p=0.794) and,80 or $80 years (3.36¡1.49 versus 3.15¡1.23 mg/day, p = 0.433). In 88 (79%) patients, the daily
warfarin dose was between 2 and 5 mg/day; in 13 (11%) patients, the daily warfarin dose was ,2.0 mg/day; and in
11 (10%) patients, the daily warfarin dose was .5.0 mg/day. The correlation between the daily warfarin dose and
the international normalized ratio was 0.22 (p=0.012).
CONCLUSION: Stable anticoagulation was achieved in 80% of patients who received doses of 2 to 5 mg/day of
warfarin, and the mean daily dose was similar across the age groups analyzed.
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INTRODUCTION
Chronic atrial fibrillation (AF) is more prevalent in the
elderly population and serves to increase the risk of
thromboembolic events. Oral anticoagulation therapy with
warfarin is highly effective for the prevention of thromboem-
bolic events (1,2). However, only half of the patients with AF
are within the therapeutic range of anticoagulation, whereas
the other half does not use oral anticoagulants (3) or are
inadequately anticoagulated (4). Currently, oral anticoagula-
tion therapy with warfarin requires regular control of the
levels of anticoagulation based on an international normalized
ratio (INR) between 2 and 3 (INR2-3) (5). It is known that
elderly patients are more likely to experience both throm-
boembolic events and bleeding, even when they are within the
therapeutic range of anticoagulation (6). For example, intra-
cranial bleeding occurs more frequently in very elderly
patients ($85 years) and those with an INR value .3.5 (7).
According to this increased bleeding risk in the elderly,
physiciansmay tolerate nontherapeutic INR levels or prescribe
lower doses of warfarin than the nonelderly would receive,
which leads to a bias that favors inadequate and ineffective
anticoagulation (8). Previous studies have demonstrated the
efficacy and safety of chronic oral anticoagulation with
warfarin in elderly patients by adopting an INR range between
2 and 3 (INR2-3). Patients with AF who remained within the
INR2-3 therapeutic range for more than 70% of the antic-
oagulation time had nearly an 80% reduction in the risk of
stroke (9). However, the average warfarin dose used in these
studies is unknown, especially the mean dose in patients with
INRs within the ideal range. Therefore, the current study
aimed to analyze the average warfarin dose for anticoagula-
tion in patients with chronic, stable INR2-3 scores. By
providing a definition of the appropriate dose for these
patients, we aim to provide health professionals with the safest
warfarin dose, thus reducing the risk of bleeding and adjusting
the dynamics of the laboratory analysis for anticoagulation.
MATERIALS AND METHODS
From a population of 2,000 individuals undergoing chro-
nic oral anticoagulation with warfarin, mostly to prevent
Copyright  2012 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
CLINICS 2012;67(6):543-546 DOI:10.6061/clinics/2012(06)01
543
thromboembolic events in patients with AF, we selected 112
ambulatory elderly patients ($65 years) who had received
consecutive anticoagulation therapy with warfarin for more
than 1 year and who had been INR2-3 stable for $6 months.
These patients were divided into two groups according to the
following age categories: ,75 or $75 years and ,80 or $80
years. We included only patients with AF and excluded
patients with renal disease (creatinine levels .2.0 mg/dL)
and uncompensated hepatic cancer or known endocrine
diseases. We also excluded patients who had bleeding or
significant changes in their INR in the preceding six months.
The tolerable INR range was 1.8 to 3.2. The control routine
outpatient anticoagulation analysis consisted of periodic
visits to the doctor every two months with concomitant
INR analysis. The Ethics Committee of the Heart Institute
(InCor) approved this study, and written informed consent
was obtained from all participants. Coagulation measure-
ments were made using an automated method in our clinical
laboratory, and the INR valuewas calculated according to the
plasma clotting time of the patient divided by the clotting
time of a normal control, raised to the power of the
International Sensitivity Index (ISI). The venous blood
samples were collected in tubes containing sodium citrate
3.8%. The plasmawas obtained by centrifugation at 3000 rpm
for 15 minutes and then analyzed using the Tcoag Destiny
MaxTM (Trinity Biotech, Ireland) automated equipment. Also,
a specific kit (PT Tcoag TriniCLOT Excel S) containing
thromboplastin extracted from rabbit brain tissue was used,
and this method had an ISI of 1.2. Normal, abnormal, and
normal pooled plasma internal controls (TRINICHECK
CONTROL - Trinity Biotech) were prepared in the laboratory
and tested daily to assess the reliability and efficiency of the
laboratory procedures to generate valid results. The results
were divided into the following three groups according to the
INR value obtained: INR,2.0, insufficiently anticoagulated
patients; INR$2.0 but ,3.5, appropriately anticoagulated
patients; and INR$3.5, excessively anticoagulated patients.
Statistical analysis
Sample size was calculated based on the differences
between the 0.5 mg dose of warfarin and the average 1.5 mg
standard deviation for patients ,75 or $75 years, which
resulted in 46 individuals for each group. The categorical
variables were analyzed using the x2 test, and continuous
variables were analyzed using the unpaired Student’s t-test.
A simple linear regression was used to analyze the
correlation between the INR versus the daily warfarin dose.
p-values,0.05 were considered statistically significant. The
statistical software used was the ‘‘Primer of Biostatistics’’
version 4.02 (10).
RESULTS
The mean age of the selected patients was 79.3¡5.57 years
with a range from 65 to 98 years. Of these, 47 (42%) patients
were male, and 65 (58%) were female. Regarding patient
distribution by age, 27 patients were 65 to 75 years of age, 69
patients were 76 to 85 years of age, and 16 patients were $85
years of age. The average daily warfarin dose to maintain
INR2-3 were similar for patients,75 or$75 years (3.34¡1.71
versus 3.26¡1.27 mg/day, p=0.794) and patients ,80 or
$80 years (3.36¡1.49 versus 3.15¡1.23 mg/day, p=0.433)
(Table 1). To achieve INR2-3, 88 (79%) patients received daily
warfarin doses of 2 to 5 mg; 13 (11%) patients received doses
,2 mg/day, and 11 (10%) patients received doses .5 mg/
day. The correlation between the daily warfarin dose and the
INR value was 0.22 (p=0.012) (Figure 1).
DISCUSSION
This study demonstrates that 80% of patients had INRs
within the optimal oral anticoagulation range (2.0 to 3.0)
after receiving warfarin doses of 2-5 mg/day, and the mean
dose was similar for both elderly age groups analyzed (,75
or $75 years and ,80 or $80 years). Previous studies have
demonstrated the importance of maintaining a stable INR
value between 2.0 to 3.0 for reducing strokes and mortality
in patients with AF. The INR value remained within the
therapeutic range more than 70% of the time, and age has
been shown not to prevent patients from maintaining INRs
within the recommended anticoagulation range (9,11,12).
The stability of the INR value resulting from these doses
facilitated anticoagulation in elderly patients, as well as the
frequency of laboratory control. Furthermore, these doses
may result in a smaller number of patients with an
inadequate INR value (,2.0) and, therefore, increased
protection from thromboembolic events and major bleeding.
A recent study on patients with stable anticoagulation, time
within the therapeutic range .70%, and effective INR2-3
values demonstrated daily doses similar to those observed
in our study (6). These authors also showed progressive
reduction in the warfarin dose with increasing age, as
43 mg/week for patients aged 41 to 50 years was reduced to
24 mg/week for the 81- to 90-year-old age group. However,
disconcordant with our study, this dose reduction was
Table 1 - Daily warfarin doses in 112 patients with atrial
fibrillation undergoing oral anticoagulation.
Groups Age N
Dose mg/day
(mean¡SD)
Minimum
dose
(mg/day)
Maximum
dose
(mg/day)
,75 or $75
years
,75 27 3.34¡1.71a 1 7.14
$75 85 3.26¡1.27a 0.57 7.14
,80 or $80
years
,80 66 3.36¡1.49b 1 7.14
$80 46 3.15¡1.23b 0.57 7.14
Total 112 3.28¡1.39 0.57 7.14
SD= standard deviation; a, 75 vs. $75 years-old, p=0.794; b , 80 vs. $80
years-old, p=0.433.
Figure 1 - A simple linear regression analysis comparing the daily
warfarin dose and the international normalized ratio is pre-
sented.
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statistically significant for the ten-year difference in the age
group .40 years. In our study, the mean warfarin dose was
similar between the groups of elderly individuals ($65
years) for the threshold ages of 75 years or 80 years.
Inadequate anticoagulation is frequent (13), and one recent
study that presented a systematic review of several other
studies showed that many patients with AF are either
inadequately anticoagulated or do not receive anticoagula-
tion therapy (14). In a previous study, patients with INRs
between 1.5 and 1.9 had a higher recurrence of venous
thromboembolism compared to patients with INRs between
2.0 to 3.0, and this range of INR values was also not
associated with a reduced risk of clinically significant
bleeding over a follow-up period of 2.4 years (15). As
compared to the optimal range of anticoagulation (INR2-3),
we observed a significantly increased risk of ischemic stroke
in patients with INRs ,1.8 as well as a risk of hemorrhagic
stroke in patients with INRs .3.5, regardless of age or a
high CHADS2 score (16). These results confirm the lack of
an effect of age on complications related to inadequate
anticoagulation (17). Other studies have also shown that the
stability of INR2-3 was independently linked to elderly
patients (.70 years) (18,19), and other independent vari-
ables identified in these studies included the absence of
heart failure, clinically significant associated diseases, and
diabetes. The absence of a significant relationship between
the INR value and warfarin dose stresses the importance of
individual variability, and, therefore, the need to develop a
safe, therapeutic treatment window for elderly patients. In
our study, the correlation between the INR value and the
daily dose of warfarin was statistically significant but low
(r = 0.22, p= 0.012), and the therapeutic window consisted of
a daily dose from 2 to 5 mg. The definition of a warfarin
dose that results in stable anticoagulation could also be used
to promote patient adherence to this treatment process. The
consensus statement of the American Heart Association/
American College of Cardiology/European Society of Cardiology
recommends a monthly laboratory analysis of patients on
oral anticoagulation with warfarin with stable INRs between
2 and 3 (20). However, laboratory analyses are typically
conducted over longer periods, e.g., every two months for
patients with stable anticoagulation. Thus, additional studies
are needed to determine the appropriate frequency of control
laboratory analysis for this group of patients, but in the
absence of significant changes in feeding routines, medica-
tions, and complications related to new diseases, the period
for control analysis may be further extended. Similarly, in
stable patients, anticoagulation control can be performed by
other health professionals, such as nurses and pharmacists,
who are involved in medical supervision. This would likely
further reduce the costs of anticoagulation, and the effective-
ness of these procedures has been documented (21,22). Cost
reduction while maintaining the efficacy of anticoagulation
could also be obtained by caring for patients receiving
anticoagulation in groups, instead of seeing each patient
individually (23). Another option for patients with stable
anticoagulation is self-control of the INR value for adjusting
the warfarin dose (24).
INR2-3 was obtained in 80% of AF patients aged $65
years with stable chronic anticoagulation when these
patients were given warfarin doses of 2 to 5 mg/day. The
mean daily dose of warfarin was similar for the elderly age
groups studied. Moreover, the doses of warfarin mentioned
above can be used to provide safe anticoagulation for most
patients, and stable anticoagulation will likely provide a
significant cost reduction.
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